Joana Hygino

Joana Hygino

Auto-generated profile, based on publicly available information

Joana Hygino

Department of Microbiology and Parasitology, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Kidney International
Verified
Journal Article
Closed access
MRMichelle Rosenzwajg
Michelle Rosenzwajg
ELEva Languille
Eva Languille
HDHanna Debiec
Hanna Debiec
JHJoana Hygino
Joana Hygino
KDKarine Dahan
Karine Dahan
PRPierre Ronco
Pierre Ronco

1 December 2010 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
MVMorgana M.M. Vieira
Morgana M.M. Vieira
TFThais B. Ferreira
Thais B. Ferreira
PPPaulo Anastácio Furtado Pacheco
Paulo Anastácio Furtado Pacheco
PBPriscila O. Barros
Priscila O. Barros
CACarla R.M. Almeida
Carla R.M. Almeida
CBCleonice A.M. Bento
Cleonice A.M. Bento

6 June 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
PSPriscila M. Sacramento
Priscila M. Sacramento
CMClarice Monteiro
Clarice Monteiro
ADAleida S. O. Dias
Aleida S. O. Dias
TKTaissa M. Kasahara
Taissa M. Kasahara
TFThaís B. Ferreira
Thaís B. Ferreira
CBCleonice A. M. Bento
Cleonice A. M. Bento

1 December 2015 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
PBP O Barros
P O Barros
TCT Cassano
T Cassano
JHJ Hygino
J Hygino
TFT B Ferreira
T B Ferreira
NCN Centurião
N Centurião
CBC A M Bento
C A M Bento
Summary: T helper type 17 (Th17) cytokines have been implicated in the pathogenesis of neuromyelitis optica (NMO). As humanized anti-interleukin (IL)-6R (tocilizumab) immunoglobulin (Ig)G has been used as disease-modifying therapy for NMO, the objective of our study was to investigate the role of endogenous IL-6 on NMO-derived CD4+ T cell behaviour. High production of IL-6, IL-17 and IL-21 by CD4+ T-cells was detected in NMO patients. Further, IL-21 and IL-6 levels were related directly to the level of neurological disabilities. The addition of anti-IL-6R IgG not only reduced directly the production of these cytokines, but also almost abolished the ability of activated autologous monocytes in enhancing IL-6, IL-17 and IL-21 release by CD4+ T cells. In contrast, the production of IL-10 was amplified in those cell cultures. Further, anti-IL-6R monoclonal antibodies (mAb) also potentiated the ability of glucocorticoid in reducing Th17 cytokines. Finally, the in-vivo and in-vitro IL-6 levels were significantly higher among those patients who experienced clinical relapse during 2-year follow-up. In summary, our results suggest a deleterious role of IL-6 in NMO by favouring, at least in part, the expansion of corticoid-resistant Th17 cells.

5 September 2012 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
ULUlisses C. Linhares
Ulisses C. Linhares
PSPatrícia B. Schiavoni
Patrícia B. Schiavoni
PBPriscila O. Barros
Priscila O. Barros
TKTaissa M. Kasahara
Taissa M. Kasahara
BTBruna Teixeira
Bruna Teixeira
CBCleonice A. M. Bento
Cleonice A. M. Bento

1 April 2016 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
HAHelcio Alvarenga-Filho
Helcio Alvarenga-Filho
PSPriscila M. Sacramento
Priscila M. Sacramento
TFThais B. Ferreira
Thais B. Ferreira
JHJoana Hygino
Joana Hygino
JAJorge Eduardo Canto Abreu
Jorge Eduardo Canto Abreu
CBCleonice A.M. Bento
Cleonice A.M. Bento